CrystalGenomics, Inc. is a Korea-based company engaged in the provision of biotechnology services. The Company operates in three business divisions: research and development division, new drug development division and structure determination research division. Its research and development division provides analysis of clinical trials services. Its new drug development division engages in the development of anti-cancer remedies, antibiotics, diabetes treatments, remedies for hypoxia diseases, obesity treatment medicines and others. Its structure determination research division provides three dimensional (3D) structure determination services to overseas pharmaceutical and bio companies. On May 12, 2011, the Company acquired entire shares of SPL, Inc., mainly engaged in the provision of biotechnology analysis support services. On On August 3, 2011, the Company completed the merger with its wholly owned subsidiary, mainly engaged in the bio-animation and analysis support business.